Yearly lenacapavir injection for HIV prevention shows safety and long-lasting effects, according to clinical trial results.

Gilead Sciences hits a 52-week high buoyed by investor optimism. We believe there is still room for growth and recommend the ...

The Conference on Retroviruses and Opportunistic Infections 2025 (CROI) featured multiple sessions that focused on breaking research and treatments.

FDA grants Fast Track designation to Johnson & Johnson’s investigational therapy nipocalimab for the treatment of moderate-to-severe Sjögren’s disease, which could be the first targeted therapy ever ...